Products

SleepStageML
Beacon Biosignals
Neurology AI
SleepStageML is an FDA-cleared AI/ML software by Beacon Biosignals that automates sleep staging from polysomnography (PSG) recordings to assist clinicians in diagnosing sleep and sleep-related disorders.

See all 1 product →

About Beacon Biosignals

Beacon Biosignals is a leading neurotechnology company that is transforming brain health through the application of artificial intelligence to brain data. For physicians, their platform integrates FDA-cleared wearable EEG technology, such as the Waveband device, with advanced AI to capture and analyze real-world neural data during both sleep and wakefulness. This approach moves gold-standard neurophysiology out of traditional lab settings and into patients’ homes, providing ecologically valid and longitudinal measures of brain function across diverse populations.

The company’s core technology, the Beacon Platform, leverages large-scale, clinically validated EEG data and proprietary machine learning algorithms to generate objective, quantitative biomarkers of brain function. These neurobiomarkers are crucial for accelerating drug development, improving diagnostics, and guiding new treatments across neurology, psychiatry, and sleep medicine. By identifying early disease signatures, predicting treatment response, and characterizing patient populations, Beacon Biosignals aims to provide more targeted, data-driven therapeutic development and ultimately enhance patient care for conditions like epilepsy, sleep disorders, Parkinson’s disease, Alzheimer’s disease, and clinical depression.

Focus Areas

Neurology Psychiatry Sleep Medicine AI-driven Neurotechnology EEG Analysis Precision Medicine Neurobiomarkers Drug Development Clinical Trials Digital Health

Business Intelligence

Key InvestorsInnoviva, Google Ventures (GV), Nexus NeuroTech Ventures, S32, Catalio Capital Management, Takeda, General Catalyst, Logos Capital, Casdin Capital, Indicator Ventures, JSL Health, Palo Santo VC, Kicker Ventures, Samsung Next, Alumni Ventures, Half Court Ventures, Iaso Ventures, Andy Beck
PartnershipsTakeda (multi-year expansion for narcolepsy diagnosis and neurobiomarker discovery, expanded in 2024/2025), Harmony Biosciences (Phase 3 studies for Narcolepsy and Idiopathic Hypersomnia, Dec 2025), Stratus (AI-powered decentralized clinical trials, May 2022), UCB, Syndeio, Novartis, Praxis Precision Medicines, Cyclerion Therapeutics, Idorsia, Bristol-Myers Squibb (BMS)
AcquisitionsCleveMed's home sleep-testing (HST) technology, Dreem's Research and Development business (July 2023)
TechnologyAI-driven platform, FDA-cleared wearable EEG technology (Waveband/Dreem 3S headband), proprietary machine learning algorithms, large-scale clinico-EEG database, cloud-native infrastructure, APIs for multimodal data streams, web-based dashboards and analytics.
FDA Clearances2 cleared products (estimated)

What Physicians Need to Know

Neurology
Beacon Biosignals focuses on transforming how neurological conditions are diagnosed, treated, and understood by making EEG brain scans a more reliable and useful data source. Their technology helps identify subtypes of neurological disorders like epilepsy and Alzheimer's, enabling neurologists to understand which patients respond best to specific therapies.
Psychiatry
The company applies quantitative sleep endpoints to better assess treatment impact on sleep and gain deeper insight into disease mechanisms for psychiatric disorders such as major depressive disorder (MDD), schizophrenia, and bipolar disorder. They aim to bring precision psychiatry through innovative biomarker insights and technology.
Sleep Medicine
Beacon Biosignals is a leader in sleep data analytics, utilizing quantitative sleep analysis to assess a wide range of indications faster and more accurately. Their FDA-cleared Waveband (formerly Dreem 3S) headband collects high-fidelity sleep EEG at home, providing objective sleep endpoints for diagnosing and evaluating sleep disorders like narcolepsy and idiopathic hypersomnia.
AI-driven Neurotechnology
At its core, Beacon Biosignals leverages advanced AI and machine learning algorithms to interpret brain data. Their AI models are trained on millions of hours of EEG data to characterize brain function, uncover early disease signatures, and predict treatment response, accelerating drug development for unmet medical needs.
EEG Analysis
The company specializes in advanced EEG analysis, utilizing their FDA-cleared Waveband (Dreem 3S) EEG headband to capture clinical-grade sleep and wake EEG data at home or in clinical settings. Their platform, including SleepStageMLu2122, automatically stages sleep from EEG signals, reducing subjective variability and increasing precision in sleep measurements.
Precision Medicine
Beacon Biosignals is bringing precision neuroscience to clinical trials by using AI-powered technology to identify individual biomarkers and disease subtypes. This approach aims to tailor treatment strategies and predict disease progression, ultimately leading to more personalized and effective therapies.
Neurobiomarkers
They are focused on the discovery and deployment of EEG neurobiomarkers. Their platform generates AI-derived biomarkers to support diagnosis, patient selection, and CNS drug development, helping to identify novel biomarkers, treatment effects, and patient stratification.
Drug Development
Beacon Biosignals accelerates drug development by providing objective, quantitative biomarkers of brain function, optimizing trials with objective sleep endpoints, and differentiating treatments through real-world evidence. They offer full-service clinical trial support, managing device setup, software integration, data quality, and reporting.
Clinical Trials
Their platform is an end-to-end solution for EEG biomarkers in clinical research, offering clinical-grade sleep EEG capture, low-latency event monitoring, and full-service clinical trial support. They enable the integration of at-home EEG into clinical trials to identify treatment signals earlier and faster.
Digital Health
Beacon Biosignals is a leader in at-home EEG and computational neurodiagnostics, utilizing FDA-cleared wearable EEG technology (Waveband) for remote data collection. This digital health approach alleviates patient burden and improves the diagnostic journey by enabling faster sleep testing and longitudinal monitoring in real-world environments.
Physician Tip

For physicians, Beacon Biosignals offers a powerful suite of tools to enhance diagnostic precision and treatment efficacy. Their FDA-cleared at-home EEG devices (Waveband) provide objective, longitudinal brain activity data, moving gold-standard neurophysiology out of the lab and into patients' homes. This allows for earlier insights into disease progression, more accurate diagnosis of complex neurological and sleep disorders (like narcolepsy), and the ability to monitor treatment response with quantitative measures. The AI-driven analytics can help identify patient subtypes, guiding personalized treatment plans and potentially improving patient outcomes in neurology, psychiatry, and sleep medicine. By reducing subjective variability in EEG interpretation and providing actionable insights, Beacon Biosignals empowers physicians to make more informed and timely clinical decisions.

Beacon Biosignals' platform is designed for seamless integration into clinical research and drug development workflows. They actively collaborate with biopharmaceutical companies (e.g., Takeda, Harmony Biosciences, Syndeio Biosciences, Bristol-Myers Squibb, UCB, Novartis) to leverage their neurophysiology platform, including the Waveband headband and AI-powered analytics, for clinical trials. This enables sponsors to integrate digital solutions into clinical trials, identify treatment signals earlier, and utilize objective EEG biomarkers for efficacy monitoring, patient stratification, and clinical trial endpoints. Their platform supports every stage of therapeutic development, from discovery to clinical practice, by extracting meaningful insights from EEG data and optimizing trials with objective sleep endpoints.

Products by Beacon Biosignals

1 product in the directory

SleepStageML
Beacon Biosignals
Neurology AI
SleepStageML is an FDA-cleared AI/ML software by Beacon Biosignals that automates sleep staging from polysomnography (PSG) recordings to assist clinicians in diagnosing sleep and sleep-related disorders.

What the Web Says

Beacon Biosignals is a neurotechnology company that develops an AI-based platform and FDA-cleared wearable EEG devices, like the Dreem 3S, to monitor brain activity during sleep for diagnostics and therapeutic development in neurological and psychiatric disorders. The company partners with pharmaceutical companies for clinical trials, aiming to create a comprehensive dataset and foundation model of the brain. While the company offers remote work flexibility and emphasizes work-life balance, some employee reviews indicate periods of intense work pressure due to external deadlines and potential resourcing strain.

Overall: Mixed

Strengths

  • FDA-cleared wearable EEG device for at-home sleep monitoring.
  • AI-powered platform for neurobiomarker discovery and analysis of large clinical neurophysiology datasets.
  • Partnerships with pharmaceutical companies for clinical trials in various neurological and psychiatric conditions.
  • Focus on creating a comprehensive foundation model of the brain from sleep data.
  • Offers remote/hybrid flexibility and emphasizes work-life balance.
  • Provides competitive benefits including healthcare, generous PTO, and parental leave.

Limitations

  • Base pay reportedly ~20% below the biotech market average, with compensation leaning towards equity.
  • Work-life balance can be mixed, with flexibility tempered by intense pushes around externally driven milestones.
  • Potential for stagnant pay progression and limited transparency on benefit plan specifics.
  • Leadership described as overwhelmed during tougher fundraising periods, indicating resourcing strain.
  • Some Reddit discussions about other companies named 'Beacon AI' or 'Beacon Group' suggest scam-like activities, which could cause confusion.
  • Limited public product reviews on platforms like G2 and Capterra specifically for Beacon Biosignals' neurotechnology products, with most reviews for other software products also named 'Beacon'.

Based on reviews from: SimplyHired, Built In, Indeed.com, Reddit, Xtalks, MIT News, G2, Capterra, PitchBook, Sleep Review, MDPI

Last updated: 2026-07-17

Videos

News, demos, and interviews about Beacon Biosignals.

Loading videos...

Videos load interactively. If none appear, search YouTube for Beacon Biosignals →

View all on YouTube

Press & Coverage

MIT News
Beacon Biosignals is mapping the brain during sleep | MIT News
Beacon Biosignals, founded by MIT alumni, is using a lightweight EEG headband and machine learning to monitor brain activity during sleep at home, aiming to accelerate treatments for neurological disorders and create a 'foundation model' of the brain.
2026-05
GlobeNewswire
Beacon Biosignals Unifies Brands, Bringing CleveMed and SleepViewu00ae Under the Beacon Name
Beacon Biosignals announced the full integration of CleveMed and its SleepViewu00ae device and home testing service under the Beacon brand, expanding its home sleep diagnostics with EEG-enabled testing.
2026-06
Beacon Biosignals
Beacon Biosignals Upsizes Series B Financing to Over $97 Million
Beacon Biosignals announced an extension to its Series B financing, bringing the total funding round to $97 million and cumulative funding to over $132 million, with new investors including JSL Health, Palo Santo VC, Kicker Ventures, and Samsung Next.
2026-04
Beacon Biosignals
Beacon Biosignals Named in Fast Company's Most Innovative Companies of 2026!
Beacon Biosignals was recognized by Fast Company as one of the Most Innovative Companies of 2026.
2026-03
Beacon Biosignals
Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG
Beacon Biosignals partnered with Harmony Biosciences to advance objective clinical endpoints in hypersomnia conditions using quantitative EEG.
2025-12
Beacon Biosignals
Beacon Biosignals Announces Multi-Year Expansion of Strategic Collaboration with Takeda to Advance Narcolepsy Diagnosis and Neurobiomarker Discovery
Beacon Biosignals expanded its strategic collaboration with Takeda to accelerate data-driven development of sleep biomarkers and patterns, supporting new diagnostic pathways for narcolepsy.
2025-11
Beacon Biosignals
Beacon Biosignals Raises $86M to Accelerate AI-Driven Insights into Brain Health
Beacon Biosignals announced an oversubscribed $86 million Series B funding round to build the world's largest neurodiagnostic dataset and advance AI-driven biomarkers for brain health.
2025-11
PR Newswire
BEACON BIOSIGNALS EXPANDS SLEEP ANALYSIS CAPABILITIES WITH FDA CLEARANCE OF SLEEPSTAGEML
Beacon Biosignals received FDA 510(k) clearance for SleepStageMLu2122ufe0f, an advanced machine learning software that automatically stages sleep from EEG signals to aid in the diagnosis and evaluation of sleep disorders.
2024-03

Frequently Asked Questions

Beacon Biosignals offers the Beacon Platform, an end-to-end solution that includes the FDA-cleared Waveband EEG headband (formerly Dreem 3S) for at-home brain data collection, the Beacon Datastore, and AI-driven analytics like SleepStageML. These products are designed to unlock objective neurobiomarkers from EEG data to transform diagnosis, treatment, and understanding across neurological, psychiatric, and sleep disorders, including conditions like epilepsy, depression, narcolepsy, and Alzheimer's disease.
Beacon Biosignals utilizes advanced AI and machine learning algorithms, trained on millions of hours of clinically validated EEG data, to identify novel neurobiomarkers. This enables precision medicine by providing objective measures of brain function, helping to stratify patient populations, detect dose-dependent drug effects, and track disease progression, ultimately accelerating drug development and improving treatment targeting.
Beacon Biosignals provides an end-to-end platform for integrating EEG biomarkers into all stages of therapeutic development, from discovery to clinical practice. They offer full-service clinical trial support, including device setup, software integration, data quality management, and reporting, helping biopharma partners optimize trials with objective sleep endpoints and differentiate treatments through real-world evidence.
Beacon Biosignals' Waveband EEG headband and SleepStageML AI for sleep staging are FDA-cleared medical devices, ensuring regulatory compliance. SleepStageML is notably the first medical device in sleep to receive FDA clearance with a Predetermined Change Control Plan (PCCP), allowing for continuous, validated improvements to their AI algorithms while maintaining safety and efficacy standards. Their at-home monitoring solutions are designed for high patient usability and secure data collection, addressing digital health concerns by bringing gold-standard neurophysiology into real-world settings.
While specific pricing details are not publicly disclosed, Beacon Biosignals primarily operates on a business-to-business model, partnering with biopharmaceutical companies and research organizations. Their services likely involve licensing fees for their platform and data, as well as service fees for clinical trial support and scientific consulting. Healthcare organizations can access support through their dedicated Clinical Study Operations and Scientific Services teams, who manage device deployment, data integration, and ongoing project needs.
Beacon Biosignals has established strategic partnerships with leading biopharmaceutical companies such as Takeda, Harmony Biosciences, Syndeio Biosciences, Bristol-Myers Squibb, UCB, and Novartis, as well as digital health companies like Koneksa and Stratus. The company demonstrates strong financial stability with over $132 million in total funding, including a recent $97 million Series B extension, backed by prominent investors like Google Ventures (GV) and Samsung Next, indicating significant investor confidence and a positive growth outlook.

Investors

Who's funded Beacon Biosignals.

Related Companies

Google DeepMind is a leading artificial intelligence (AI) research laboratory, a subsidiary of Alphabet Inc., dedicated to developing advanced AI systems to benefit humanity. The company focuses on creating general-purpose AI that can learn and solve complex problems, drawing inspiration from neuroscience and machine learning. Their work spans various fields, including healthcare, scientific discovery, and […]

TalkToMedi is a Canadian healthcare AI company that has developed a clinical-grade voice AI platform called MEDI. This platform is designed to automate patient communication and administrative tasks for medical clinics, including family medicine, specialty clinics, allied health, and physiotherapy. MEDI handles high-volume patient calls, automating appointment inquiries, booking, rescheduling, and cancellations based on the […]

Menaela is an AI-first practice management system designed for solo practitioners, small private clinics, and clinic owners. It integrates patient communication, scheduling, CRM, and medical documentation into a single platform, aiming to replace multiple disconnected tools and bots. The system features an AI practice manager that understands natural-language requests, utilizes real clinic data, and performs […]

Avie is operated by AVIE TECNOLOGIA LTDA, headquartered in Santo André, São Paulo, Brazil. Avie provides WhatsApp reception in Brazilian Portuguese, appointment scheduling, rescheduling and cancellations through Google Calendar or Feegow, clinic CRM, follow-up messages and an online booking website. Clinic staff can review conversations and take over when human support is needed. Clinic CRM […]

Saile is a physician-founded healthcare technology company that addresses critical inefficiencies in healthcare staffing and credentialing. Their AI-powered platform acts as a “universal credential passport” for physicians, centralizing and managing all medical licenses, certifications, and CME credits in one secure, portable vault. This system aims to significantly reduce the administrative burden and delays associated with […]

Data Capture Experts (DCE) is an Australian-based healthcare AI company that is at the forefront of digital health transformation. They specialize in developing and implementing digital health platforms that integrate data, technology, and human-centered design to create intuitive and connected healthcare systems. Their flagship platform, DC2Vue, is designed to go beyond traditional Electronic Medical Records […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.